<DOC>
	<DOCNO>NCT00356681</DOCNO>
	<brief_summary>To determine treatment paclitaxel plus AMG 706 superior paclitaxel plus AMG 706 placebo subject HER2 negative locally recurrent metastatic breast cancer . Also estimate difference treatment paclitaxel plus AMG 706 paclitaxel plus bevacizumab .</brief_summary>
	<brief_title>A Study AMG 706 Bevacizumab , Combination With Paclitaxel Chemotherapy , Treatment Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast locally recurrent metastatic disease . Measurable disease RECIST guideline . Tumor ( primary metastatic ) must HER2 negative . Adequate organ hematologic function . Exclusion : Taxane treatment within 12 month prior registration . Prior chemotherapy locally recurrent metastatic breast cancer ( prior endocrine therapy permit ) . Prior radiation therapy , radiofrequency ablation , percutaneous cryotherapy hepatic chemoembolization sit measurable disease . Current prior history central nervous system metastasis . Peripheral neuropathy â‰¥ grade 2 ( CTCAE v3.0 ) registration . History arterial venous thrombosis within 1 year prior registration . History bleed diathesis bleeding within 14 day registration . Uncontrolled hypertension ( systolic &gt; 145 mmHg ; diastolic &gt; 85 mmHg ) . Clinically significant cardiac disease within 12 month registration . Known HIV positive , hepatitis C positive hepatitis B surface antigen positive . Prior treatment VEGFr target therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>AMG 706</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Antiangiogenic</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>